Cat. No.: HY-19745

BMS-202

25 Cited Publications

Avis client

Based on 25 publication(s) in Google Scholar

BMS-202 is a potent and nonpeptidic PD-1/PD-L1 complex inhibitor with an IC₅₀ of 18 nM and a K_D of 8 μM. BMS-202 binds to PD-L1 and blocks human PD-1/PD-L1 interaction. BMS-202 has antitumor activity.

Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.

Pureté: 99.48%
CAS No.: 1675203-84-5
Formule: C₂₅H₂₉N₃O₃
Masse moléculaire:419.52

Stockage:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 1 year , -20°C, 6 months

BMS-202 Chemical Structure

CAS No.: 1675203-84-5

Size

Prix

Stock

Quantité

Sample (0.1mg)

In-stock

(In Japan)

Apply Now

Obtenir un devis Ask For Quote & Lead Time Consult sales personnel for more information Check price and availability Obtenir un devis Ask For Quote & Lead Time Consult sales personnel for more information Check price and availability

Bulk Inquiry

Amount: USD 0.00

* Veuillez sélectionner la quantité avant d'ajouter des articles.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Activité biologique
- Description
- IC₅₀ & Target
- Cellular Effect
- In Vitro
- In Vivo
Chemical Information
Publications (25)
Solvant et solubilité
- In Vitro
- In Vivo
Pureté et documentation
Références
Help & FAQs
Bioz

Activité biologique

Description

IC₅₀ & Target

IC50: 18 nM (PD-1/PD-L1)^[1]
KD: 8 μM (PD-1/PD-L1)^[1]

Cellular Effect

Cell Line	Type	Value	Description	References
4T1	IC₅₀	5.2 μM Compound: 1; BMS-202	Antiproliferative activity against mouse 4T1 cells as cell killing incubated for 6 days by CCK-8 assay Antiproliferative activity against mouse 4T1 cells as cell killing incubated for 6 days by CCK-8 assay	[PMID: 38348878]
CHO	EC₅₀	24.9 μM Compound: BMS-202	Cytotoxicity against CHO cells expressing human PD-L1 assessed as cell viability measured after 24 hrs by MTT assay Cytotoxicity against CHO cells expressing human PD-L1 assessed as cell viability measured after 24 hrs by MTT assay	[PMID: 38442487]
CHO-K1	GI₅₀	4.5 μM Compound: 1a	Cytotoxicity against CHOK1 cells stably expressing human PDL1 co-cultured with human Jurkat T cell expressing human PD1 assessed as growth inhibition measured after 24 hrs by XTT assay Cytotoxicity against CHOK1 cells stably expressing human PDL1 co-cultured with human Jurkat T cell expressing human PD1 assessed as growth inhibition measured after 24 hrs by XTT assay	[PMID: 31298541]
CT26	IC₅₀	3.35 μM Compound: BMS-202	Antiproliferative activity against mouse CT26 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay Antiproliferative activity against mouse CT26 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay	[PMID: 34481337]
HCC827	IC₅₀	8.41 μM Compound: BMS202	Cytotoxicity against human HCC827 cells incubated for 36 hrs by standard CCK-8 assay Cytotoxicity against human HCC827 cells incubated for 36 hrs by standard CCK-8 assay	[PMID: 33949196]
HEK293	IC₅₀	96 nM Compound: 1a	Inhibition of human Fc-tagged PD1 N-terminal domain (Leu25 to Gln167 residues) expressed in HEK293 cells/human His-tagged PDL1 (Phe19 to Arg238 residues) expressed in HEK293 cells protein-protein interaction after 1 hr by APC-labeled anti-His antibody/Eu- Inhibition of human Fc-tagged PD1 N-terminal domain (Leu25 to Gln167 residues) expressed in HEK293 cells/human His-tagged PDL1 (Phe19 to Arg238 residues) expressed in HEK293 cells protein-protein interaction after 1 hr by APC-labeled anti-His antibody/Eu-	[PMID: 31298541]
HEK293	IC₅₀	99.6 nM Compound: BMS-202	Inhibition of Eu-tagged PD-1 (unknown origin)/C-terminal Fc fusion (human IgG1)/Avi-tagged biotinylated human PDL1 (19 to 239 residues) extracted from HEK293 cells interaction preincubated for 15 mins with PD-L1 followed by PD-1 addition and measured afte Inhibition of Eu-tagged PD-1 (unknown origin)/C-terminal Fc fusion (human IgG1)/Avi-tagged biotinylated human PDL1 (19 to 239 residues) extracted from HEK293 cells interaction preincubated for 15 mins with PD-L1 followed by PD-1 addition and measured afte	[PMID: 39389791]
Jurkat	EC₅₀	2764 nM Compound: 1a	Inhibition of PD1/PDL1 interaction in human Jurkat cells co-cultured with human U2OS cells expressing PDL1 assessed as reduction in SHP1 recruitment preincubated with U2OS cells for 60 mins followed by Jurkat cell addition and measured after 2 hrs by Path Inhibition of PD1/PDL1 interaction in human Jurkat cells co-cultured with human U2OS cells expressing PDL1 assessed as reduction in SHP1 recruitment preincubated with U2OS cells for 60 mins followed by Jurkat cell addition and measured after 2 hrs by Path	[PMID: 31298541]
Jurkat	GI₅₀	4.5 μM Compound: 1a	Cytotoxicity against human Jurkat T cell expressing human PD1 co-cultured with CHOK1 cells stably expressing human PDL1 assessed as growth inhibition measured after 24 hrs by XTT assay Cytotoxicity against human Jurkat T cell expressing human PD1 co-cultured with CHOK1 cells stably expressing human PDL1 assessed as growth inhibition measured after 24 hrs by XTT assay	[PMID: 31298541]
Jurkat	EC₅₀	>10000 nM Compound: 1a	Inhibition of human PD1 stably expressed in human Jurkat T cells co-expressing NFAT-induced luciferase/human PDL1 stably expressed in CHOK1 cells co-expressing aAPC protein-protein interaction assessed as increase in NFAT signaling measured after 6 hrs by Inhibition of human PD1 stably expressed in human Jurkat T cells co-expressing NFAT-induced luciferase/human PDL1 stably expressed in CHOK1 cells co-expressing aAPC protein-protein interaction assessed as increase in NFAT signaling measured after 6 hrs by	[PMID: 31298541]
Jurkat	EC₅₀	>10000 nM Compound: 1; BMS-202	Inhibition of human PD-1/PD-L1 interaction in human Jurkat cells expressing PD-1/NFAT/Luc cocultured with CHO-K1 cells expressing PD-L1/aAPC assessed as Jurkat T-lymphocyte activation measured after 6 hrs by luciferase reporter gene based luminescence ass Inhibition of human PD-1/PD-L1 interaction in human Jurkat cells expressing PD-1/NFAT/Luc cocultured with CHO-K1 cells expressing PD-L1/aAPC assessed as Jurkat T-lymphocyte activation measured after 6 hrs by luciferase reporter gene based luminescence ass	[PMID: 34115499]
Jurkat	IC₅₀	2.6 μM Compound: BMS-202	Cytotoxicity against human Jurkat cells assessed as cell growth inhibition incubated for 48 hrs by MTT assay Cytotoxicity against human Jurkat cells assessed as cell growth inhibition incubated for 48 hrs by MTT assay	[PMID: 37226718]
Jurkat	IC₅₀	4.33 μM Compound: 1; BMS-202	Antiproliferative activity against human Jurkat cells as cell killing incubated for 6 days by CCK-8 assay Antiproliferative activity against human Jurkat cells as cell killing incubated for 6 days by CCK-8 assay	[PMID: 38348878]
Jurkat	EC₅₀	1.03 μM Compound: 1; BMS202	Inhibition of PD-1 (unknown origin) expressed in Jurkat T cell membranes harboring NFAT-Luc interaction with PD-L1 (unknown origin) expressed in CHO cells assessed as Jurkat T lymphocyte activation by measuring increase in luminescence intensity measured Inhibition of PD-1 (unknown origin) expressed in Jurkat T cell membranes harboring NFAT-Luc interaction with PD-L1 (unknown origin) expressed in CHO cells assessed as Jurkat T lymphocyte activation by measuring increase in luminescence intensity measured	[PMID: 38959727]
MDA-MB-231	IC₅₀	7.92 μM Compound: BMS202	Cytotoxicity against human MDA-MB-231 cells incubated for 36 hrs by standard CCK-8 assay Cytotoxicity against human MDA-MB-231 cells incubated for 36 hrs by standard CCK-8 assay	[PMID: 33949196]
MDA-MB-231	IC₅₀	19.32 μM Compound: 1; BMS-202	Antiproliferative activity against human MDA-MB-231 cells as cell killing incubated for 6 days by CCK-8 assay Antiproliferative activity against human MDA-MB-231 cells as cell killing incubated for 6 days by CCK-8 assay	[PMID: 38348878]
T-cell	EC₅₀	11 nM Compound: BMS-202	Cytotoxicity against T cell (unknown origin) Cytotoxicity against T cell (unknown origin)	[PMID: 34954618]
U-251	IC₅₀	2.98 μM Compound: BMS-202	Antiproliferative activity against human U-251 cells incubated for 72 hrs by MTT assay Antiproliferative activity against human U-251 cells incubated for 72 hrs by MTT assay	[PMID: 38739112]
U-87MG ATCC	IC₅₀	3.72 μM Compound: BMS-202	Antiproliferative activity against human U-87 MG cells incubated for 72 hrs by MTT assay Antiproliferative activity against human U-87 MG cells incubated for 72 hrs by MTT assay	[PMID: 38739112]

In Vitro

BMS-202 (0-100 μM; 4 days; SCC-3 or Jurkat cells) treatment inhibits the proliferation of strongly PD-L1-positive SCC-3 cells (IC₅₀ of 15 μM) and anti-CD3 antibody-activated Jurkat cells (IC₅₀ 10 μM) in vitro^[2].
BMS-202 selectively induces thermal stabilization of PD-L1. BMS-202 induces dimerization of PD-L1 in solution.BMS-202 is located at the center of the homodimer filling a deep hydrophobic pocket contributing multiple additional interactions between the monomers. BMS-202 interacts with both PD-L1 molecules using hydrophobic surfaces physiologically involved in the PD-1/PD-L1 interaction^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Proliferation Assay^[2]

Cell Line:

SCC-3 or Jurkat cells
Concentration:

0-100 μM
Incubation Time:

4 days
Result:

Inhibited the proliferation of strongly PD-L1-positive SCC-3 cells (IC₅₀ of 15 μM) and anti-CD3 antibody-activated Jurkat cells (IC₅₀ 10 μM) in vitro.

In Vivo

BMS-202 (20 mg/kg; intraperitoneal injection; daily; for 9 days; NOG-dKO mice) treatment shows a clear antitumor effect compared with the controls, in humanized MHC- dKO NOG mice^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

NOG-dKO mice (8-week-old) injected with SCC-3 cells^[2]
Dosage:

20 mg/kg
Administration:

Intraperitoneal injection; daily; for 9 days
Result:

Showed 41% growth inhibitory activity against humanized mouse-transplanted human lymphoma SCC-3 cells.

Chemical Information

CAS No. 1675203-84-5
Appearance Solid
Masse moléculaire 419.52
Formule C₂₅H₂₉N₃O₃
Color White to off-white
SMILES

CC(NCCNCC1=CC=C(OCC2=C(C)C(C3=CC=CC=C3)=CC=C2)N=C1OC)=O
Livraison

Room temperature in continental US; may vary elsewhere.

Stockage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	1 year
	-20°C	6 months

Publications (25)

All Cell Migration/Invasion AssayFlow CytometryCell Proliferation/Viability AssayRT-PCRWB

Sort by:

Journal Impact Factor

ACS Nano

Immunomodulatory Prodrug Micelles Imitate Mild Heat Effects to Reshape Tumor Microenvironment for Enhanced Cancer Immunotherapy. [Abstract]

2024 Feb 20;18(7):5632-5646. PMID: 38344992
Nat Commun

Strategies to package recombinant Adeno-Associated Virus expressing the N-terminal gasdermin domain for tumor treatment. [Abstract]

2021 Dec 9;12(1):7155. PMID: 34887423
Acta Pharm Sin B

GPC3-mediated lysosome-targeting chimeras (GLTACs) for targeted degradation of membrane proteins. [Abstract]

2025 Apr;15(4):2156-2169. PMID: 40486834

BMS-202 purchased from MedChemExpress. Usage Cited in: Acta Pharm Sin B. 2025 Apr;15(4):2156-2169. [Abstract]

Effects of compounds WP0 and BMS-202 to induce T-cell-mediated tumor killing against HepG2 Cells.

BMS-202 purchased from MedChemExpress. Usage Cited in: Acta Pharm Sin B. 2025 Apr;15(4):2156-2169. [Abstract]

PD-L1 protein level in HepG2 cells. Cells were pretreated with lysosome inhibitor BafA (100 nmol/L), BMS-202 (1 μmol/L), TJ12P1 (1 μmol/L), or proteasome inhibitor MG132 (100 nmol/L), followed by treatment with WP0 (1 μmol/L).
Acta Pharm Sin B

Cancer-cell-biomimetic nanoparticles systemically eliminate hypoxia tumors by synergistic chemotherapy and checkpoint blockade immunotherapy. [Abstract]

2022 Apr;12(4):2103-2119. PMID: 35847496
Adv Sci (Weinh)

Targeted Delivery of c(RGDfk)-Modified Liposomes to Bone Marrow Through In Vivo Hitchhiking Neutrophils for Multiple Myeloma Therapy. [Abstract]

2024 Dec 16:e2409895. PMID: 39679804
J Nanobiotechnology

Autophagy-amplifying nanoparticles evoke immunogenic cell death combined with anti-PD-1/PD-L1 for residual tumors immunotherapy after RFA. [Abstract]

2023 Oct 3;21(1):360. PMID: 37789342
Nano Today

2022, 47: 101689.
EBioMedicine

MiR-873/PD-L1 axis regulates the stemness of breast cancer cells. [Abstract]

2019 Mar:41:395-407. PMID: 30803931
Biomater Res

Metal-organic framework-based photodynamic combined immunotherapy against the distant development of triple-negative breast cancer. [Abstract]

2023 Nov 24;27(1):120. PMID: 37996880

BMS-202 purchased from MedChemExpress. Usage Cited in: Biomater Res. 2023 Nov 24;27(1):120. [Abstract]

Compared with the blank control group, the PCN-224/HP NPs, BMS-202, BMS@P/HP NPs, PCN-224/HP+L and BMS@P/HP+L groups all showed different degrees of tumor cell apoptosis.
Mater Today Nano

2024 Aug.
J Med Chem

Hsp70-Targeting Chimeras Enable Dual Proteasomal and Lysosomal Degradation of Intracellular and Extracellular Proteins. [Abstract]

2026 Apr 9;69(7):8417-8432. PMID: 41874277
J Med Chem

A DNA-Mediated Lysosomal Degradation Strategy for Targeted Degradation of PD-L1 Protein. [Abstract]

2025 Jun 12;68(11):11829-11840. PMID: 40403183
J Med Chem

Discovery of Novel and Highly Potent Dual PD-L1/Histone Deacetylase 6 Inhibitors with Favorable Pharmacokinetics for Cancer Immunotherapy. [Abstract]

2025 Feb 20. PMID: 39979078
J Med Chem

Design, Synthesis, and Biological Evaluation of Linear Aliphatic Amine-Linked Triaryl Derivatives as Potent Small-Molecule Inhibitors of the Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Interaction with Promising Antitumor Effects In Vivo. [Abstract]

2020 Nov 25;63(22):13825-13850. PMID: 33186040
Cells

Immunomodulatory Effect and Bone Homeostasis Regulation in Osteoblasts Differentiated from hADMSCs via the PD-1/PD-L1 Axis. [Abstract]

2022 Oct 7;11(19):3152. PMID: 36231113
Nanoscale

Adoptive CD8+T-cell grafted with liposomal immunotherapy drugs to counteract the immune suppressive tumor microenvironment and enhance therapy for melanoma. [Abstract]

2021 Oct 1;13(37):15789-15803. PMID: 34528979
ACS Omega

Virtual Screening and Biological Evaluation of Potential PD-1/PD-L1 Immune Checkpoint Inhibitors as Anti-Hepatocellular Carcinoma Agents. [Abstract]

2023 Sep 3;8(37):33242-33254. PMID: 37744828
Drug Dev Res

The PD-1/PD-L1 binding inhibitor BMS-202 suppresses the synthesis and secretion of gonadotropins and enhances apoptosis via p38 MAPK signaling pathway. [Abstract]

2022 Feb;83(1):176-183. PMID: 34309063

BMS-202 purchased from MedChemExpress. Usage Cited in: Drug Dev Res. 2022 Feb;83(1):176-183. [Abstract]

Cultured Lβt2 cells are treated with 25 μM BMS-202 and collected at 24 h. the p-p38 MAPK, p38 MAPK, p-JNK, JNK, p-ERK, ERK, and α-tubulin protein levels are detected by Western Blotting.
ACS Pharmacol Transl Sci

Antineuroblastoma Activity Evaluation and Mechanism of Novel PD-L1 Small Molecule Inhibitors through Immune and Non-Immune Pathways. [Abstract]

2025 Jul 7;8(8):2612-2629. PMID: 40810160
Cell Signal

The role of α7nAchR and PD-L1 in neuroimmune regulation of keloid treatment. [Abstract]

2024 Jun 26:111275. PMID: 38942343
Mol Med Rep

Direct effects of the small molecule PD‑L1 inhibitor BMS‑202 on A375 melanoma cells: Anti‑tumor activity accompanied by increased mitochondrial function. [Abstract]

2025 Sep;32(3):242. PMID: 40641134

BMS-202 purchased from MedChemExpress. Usage Cited in: Mol Med Rep. 2025 Sep;32(3):242. [Abstract]

BMS-202 (5 μM, 24 h) inhibits A375 cell migration and invasion.

BMS-202 purchased from MedChemExpress. Usage Cited in: Mol Med Rep. 2025 Sep;32(3):242. [Abstract]

RT-qPCR analysis revealed an increase in the mRNA expression levels of the pro-apoptotic factor Bax and a decrease in the mRNA expression levels of the anti-apoptotic factor Bcl-2 treated with BMS-202 (5 μM, 24 h).
Mol Pain

The regulation of the PD-1/PD-L1 pathway in imiquimod-induced chronic psoriasis itch and itch sensitization in mouse. [Abstract]

2024 Jan-Dec:20:17448069241252384. PMID: 38631843
Onco Targets Ther

Remodels the Immunosuppressive Tumor Microenvironment by Combination of Bacillus Calmette-Guérin and Anti-PD-L1 in an Orthotopic Triple-Negative Breast Cancer Mouse Model. [Abstract]

2021 Mar 30:14:2247-2258. PMID: 33833524
Bio Protoc

Establishment of Human PD-1/PD-L1 Blockade Assay Based on Surface Plasmon Resonance (SPR) Biosensor. [Abstract]

2023 Aug 5;13(15):e4765. PMID: 37575393
Pharmacological Research-Modern Chinese Medicine

19 January 2022, 100051.

Solvant et solubilité

In Vitro:

DMSO : ≥ 100 mg/mL (238.37 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

* "≥" means soluble, but saturation unknown.

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

2.3837 mL

11.9184 mL

23.8368 mL

5 mM

0.4767 mL

2.3837 mL

4.7674 mL

10 mM

0.2384 mL

1.1918 mL

2.3837 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months. When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.

Calculateur de molarité

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Calculateur de dilution

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.5 mg/mL (5.96 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 2.5 mg/mL (5.96 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.5 mg/mL (5.96 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

Working Solution

For the following dissolution methods, please prepare the working solution directly:

It is recommended to prepare fresh solutions and use them promptly within a short period of time.

The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 45% PEG300 5% Tween-80 50% Saline

Solubility: 4.05 mg/mL (9.65 mM); Clear solution; Need ultrasonic

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Pureté et documentation

Select Batch:

Pureté: 99.98%

Assay: 99.98%

ee.: 99.98%

Fiche technique (275 KB)
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Portuguese - PT (393 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Instruction de manipulation (2659 KB)

Références

[1]. Zak KM, et al. Structural basis for small molecule targeting of the programmed death ligand 1 (PD-L1). Oncotarget. 2016 May 24;7(21):30323-35. [Content Brief]

[2]. Ashizawa T, et al. Antitumor activity of the PD-1/PD-L1 binding inhibitor BMS-202 in the humanized MHC-double knockout NOG mouse. Biomed Res. 2019;40(6):243-250. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months. When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	2.3837 mL	11.9184 mL	23.8368 mL	59.5919 mL
	5 mM	0.4767 mL	2.3837 mL	4.7674 mL	11.9184 mL
	10 mM	0.2384 mL	1.1918 mL	2.3837 mL	5.9592 mL
	15 mM	0.1589 mL	0.7946 mL	1.5891 mL	3.9728 mL
	20 mM	0.1192 mL	0.5959 mL	1.1918 mL	2.9796 mL
	25 mM	0.0953 mL	0.4767 mL	0.9535 mL	2.3837 mL
	30 mM	0.0795 mL	0.3973 mL	0.7946 mL	1.9864 mL
	40 mM	0.0596 mL	0.2980 mL	0.5959 mL	1.4898 mL
	50 mM	0.0477 mL	0.2384 mL	0.4767 mL	1.1918 mL
	60 mM	0.0397 mL	0.1986 mL	0.3973 mL	0.9932 mL
	80 mM	0.0298 mL	0.1490 mL	0.2980 mL	0.7449 mL
	100 mM	0.0238 mL	0.1192 mL	0.2384 mL	0.5959 mL

Keywords

BMS-202

25 Cited Publications

100 mg Obtenir un devis

Subscribe to the

MedChemExpress

Newsletter

Nom du produit:
Cat. No.:
Quantité:
MCE Japan Authorized Agent:

Nom du produit:
CAS No.:
Species:
Pureté:
Quantité:

BMS-202

Apoptosis Compound Library

Immunology/Inflammation Compound Library

Anti-Cancer Compound Library

Small Molecule Immuno-Oncology Compound Library

Peptidomimetic Library

Anti-Breast Cancer Compound Library

Anti-Lung Cancer Compound Library

Anti-Blood Cancer Compound Library

Anti-Liver Cancer Compound Library

Anti-Colorectal Cancer Compound Library

Protein-protein Interaction Inhibitor Library

Heterocyclic Compound Library

Membrane Protein-targeted Compound Library

Membrane Receptor-targeted Compound Library

Cell Death Library

Anti-Hematopathy Compound Library

Anti-Ovarian Cancer Compound Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Bioactive Compound Library

Anti-Gastric Cancer Compound Library

Anti-Brain Cancer Compound Library

Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library

High-Throughput Bioactive Compound Library

Publications Citing Use of MedChemExpress (MCE) BMS-202

Activité biologique

Chemical Information

Publications (25)

Solvant et solubilité

Pureté et documentation

Références

Help & FAQs

Complete Stock Solution Preparation Table

BMS-202

Apoptosis Compound Library

Immunology/Inflammation Compound Library

Anti-Cancer Compound Library

Small Molecule Immuno-Oncology Compound Library

Peptidomimetic Library

Anti-Breast Cancer Compound Library

Anti-Lung Cancer Compound Library

Anti-Blood Cancer Compound Library

Anti-Liver Cancer Compound Library

Anti-Colorectal Cancer Compound Library

Protein-protein Interaction Inhibitor Library

Heterocyclic Compound Library

Membrane Protein-targeted Compound Library

Membrane Receptor-targeted Compound Library

Cell Death Library

Anti-Hematopathy Compound Library

Anti-Ovarian Cancer Compound Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Bioactive Compound Library

Anti-Gastric Cancer Compound Library

Anti-Brain Cancer Compound Library

Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library

High-Throughput Bioactive Compound Library

Publications Citing Use of MedChemExpress (MCE) BMS-202

Activité biologique

Chemical Information

Publications (25)

Solvant et solubilité

Pureté et documentation

Références

Help & FAQs

Complete Stock Solution Preparation Table

BMS-202 Related Classifications

Cat. No.: HY-19745